United Therapeutics Corporation (UTHR)

Financial leverage ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Total assets US$ in thousands 7,364,000 7,123,100 6,723,200 6,495,200 7,167,000 7,023,600 6,681,300 6,346,000 6,044,500 5,781,600 5,543,300 5,359,800 5,169,100 5,048,900 4,844,900 4,641,000 4,615,000 4,411,200 4,219,400 4,025,900
Total stockholders’ equity US$ in thousands 6,444,000 6,100,900 5,697,200 5,338,100 5,984,800 5,712,100 5,411,000 5,123,200 4,796,700 4,562,200 4,318,400 4,176,300 3,958,900 3,829,700 3,639,500 3,445,400 3,395,200 3,283,100 3,093,700 2,948,500
Financial leverage ratio 1.14 1.17 1.18 1.22 1.20 1.23 1.23 1.24 1.26 1.27 1.28 1.28 1.31 1.32 1.33 1.35 1.36 1.34 1.36 1.37

December 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $7,364,000K ÷ $6,444,000K
= 1.14

United Therapeutics Corporation's financial leverage ratio has been on a declining trend over the past few years, indicating an improving financial position in terms of leverage. The ratio decreased steadily from 1.37 as of March 31, 2020, to 1.14 as of December 31, 2024. This suggests that the company has been gradually reducing its reliance on debt to finance its operations and investments, potentially lowering the associated financial risks. A lower financial leverage ratio generally indicates a healthier balance sheet and greater financial stability. It is important for investors and stakeholders to monitor this trend to assess the company's ability to meet its debt obligations and pursue growth opportunities in a sustainable manner.